Clinical TrialsThe Phase 3 TIGeR-PAC study is nearing enrollment completion, with favorable recommendations to continue.
Drug DevelopmentRenovoRx's drug delivery platform allows for the direct delivery of therapeutics to tumors that are difficult to access, which could enhance treatment effectiveness.
Financial PerformanceRenovoRx reported its fiscal Q2 2025 results with revenue exceeding estimates, indicating strong revenue growth.